GVM±R in Patients With Relapsed or Refractory Aggressive NHL.

Must have received: standard therapy

relapsed or proven refractory to at least one line of standard therapy or have achieved PR as the best response after a minimum of 4 cycles of therapy

Cannot have received: mitoxantrone or mitoxantrone liposomes (mitoxantrone, mitoxantrone liposomes)

Subjects who have been treated with mitoxantrone or mitoxantrone liposomes

Cannot have received: anthracycline (doxorubicin, epirubicin)

Exception: total cumulative dose of doxorubicin more than 360 mg/m2 (for other anthracyclines, 1 mg doxorubicin equivalent to 2 mg epirubicin)

Previously received doxorubicin or other anthracycline treatment, and the total cumulative dose of doxorubicin was more than 360 mg/m2 (For other anthracyclines, 1 mg doxorubicin equivalent to 2 mg epirubicin)

Cannot have received: anti-tumor treatment

Subjects who received anti-tumor treatment (including chemotherapy, targeted therapy, glucocorticoid, traditional Chinese medicine with anti-tumor activity, etc.) or participated in other clinical trials and received trial drugs within 4 weeks or 5 half-lives (whichever comes first) before the first administration of the study drugs

Cannot have received: autologous or allogeneic hematopoietic stem cell transplantation

Exception: within 100 days before the first administration of study drugs

Subjects who received autologous hematopoietic stem cell transplantation or allogeneic hematopoietic stem cell transplantation within 100 days before the first administration of study drugs

Cannot have received: CAR-T cell therapy

Subjects who received chimeric antigen receptor T-cell (CAR-T) therapy